EU Rejects Obesity Drug Qsiva for the Second TimeEU Rejects Obesity Drug Qsiva for the Second Time
Despite an appeal by Vivus, the European Medicines Agency has rejected the obesity treatment phentermine/topiramate extended release for the second time. Any benefit "does not outweigh the risks," says the EMA. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 26, 2013 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
CHMP recommends refusal of Qsiva® (phentermine/ topiramate) marketing authorisation following re-examination
Source: European Medicines Agency
Area: News
Following a re-examination of a previous opinion, the Committee for Medicinal Products for Human Use (CHMP) has confirmed its recommendation to refuse the marketing authorisation for Qsiva® (phentermine and topiramate), intended for the treatment of obesity.
The CHMP noted concerns about the long-term cardiovascular effects of Qsiva® (particularly those of the phentermine component, which is known to increase heart rate). There were additionally concerns about the long-term psychiatric and cognitive effects related to the topiramate component. Topiramate is also ...
Source: NeLM - News - February 25, 2013 Category: Drugs & Pharmacology Source Type: news
Meta-Analysis: Evidence of Efficacy Lacking for Pediatric Headache Prophylaxis
Topiramate and trazadone showed only limited efficacy in treating pediatric headache. No evidecne was found for flunarizine, pizotifen, propranolol, and valproate, to support their use in this population. How to use this information? (Source: Consultant Live)
Source: Consultant Live - February 16, 2013 Category: Primary Care Source Type: news
Pediatric migraine drugs show limited or no efficacy
There is limited evidence supporting the efficacy of trazodone and topiramate in the prevention of pediatric episodic migraine headaches, show results from a meta-analysis. (Source: MedWire News - Pediatrics)
Source: MedWire News - Pediatrics - January 30, 2013 Category: Pediatrics Source Type: news
Perampanel for epilepsy: No proof of added benefit
(Institute for Quality and Efficiency in Health Care) In an early benefit assessment IQWiG examined whether perampanel offers an added benefit over the previous standard therapy in people with epileptic fits. However, no such added benefit can be derived from the dossier, because the manufacturer failed to present suitable data for the comparison with lamotrigine or topiramate. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 30, 2013 Category: Global & Universal Source Type: news
